News | February 02, 2023
Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr
The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022
The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Diagnostic imaging will become an increasingly vital process in healthcare
Zidavi is recommended by the Infectious Disease Society of America
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Subscribe To Our Newsletter & Stay Updated
